<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
  <channel>
    <title>Pharmaceutical Online News</title>
    <description>News Articles</description>
    <link>http://www.pharmaceuticalonline.com/</link>
    <pubDate>Fri, 19 Mar 2010 15:20:00 GMT</pubDate>
    <item>
      <title>FDA Update: March 22, 2010</title>
      <description />
      <link>http://www.pharmaceuticalonline.com/article.mvc/FDA-Update-March-22-2010-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Fri, 19 Mar 2010 15:20:00 GMT</pubDate>
    </item>
    <item>
      <title>Teva To Acquire Ratiopharm </title>
      <description>Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has entered into a definitive agreement to acquire ratiopharm, Germany's second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of 3.625 billion. The transaction is subject to certain conditions including relevant regulatory approvals.</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Teva-To-Acquire-Ratiopharm-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Thu, 18 Mar 2010 12:56:53 GMT</pubDate>
    </item>
    <item>
      <title>Alpharma To Pay $42.5M To Resolve False Claims Act Allegations In Connection With Promotion Of Drug Kadian</title>
      <description>American pharmaceutical manufacturer Alpharma Inc. has agreed to pay $42.5M  to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug, Kadian, the Justice Department announced today.</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Alpharma-To-Pay-425M-To-Resolve-False-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Thu, 18 Mar 2010 10:15:00 GMT</pubDate>
    </item>
    <item>
      <title>Brand Protection And Cost Savings With Dynamic Weighing And Contaminant Detection In One Compact System</title>
      <description>Mettler-Toledo Hi-Speed, the worldwide leader of in-line checkweighing, announces the launch of the new XS3 AdvanChek X-ray CombiWeigher, which combines world-leading checkweighing and x-ray inspection technologies in one revolutionary and unique, space-saving system.</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Brand-Protection-And-Cost-Savings-With-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Thu, 18 Mar 2010 06:27:00 GMT</pubDate>
    </item>
    <item>
      <title>UltraCap&amp;reg; H.D. Capsule In 40-Inch Length Provides Large Volume Filtration </title>
      <description>UltraCap&amp;reg; H.D. (Heavy Duty) single-use high capacity capsule filters provide high flow rates 
and high throughput, in lengths up to 40 inches (100 cm) for large volume filtration.</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/UltraCap-HD-Capsule-in-40-inch-Length-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Thu, 18 Mar 2010 06:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Teva Provides Update On Generic Temodar®</title>
      <description>Teva Pharmaceutical Industries Ltd., announced recently that the parties to the patent litigation regarding Barr's U.S. generic version of Schering's Temodar® have entered into an agreement pending resolution of Schering's appeal to the Federal Circuit of the U.S. District Court's decision holding the '291 Patent unenforceable. </description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Teva-Provides-Update-On-Generic-Temodar-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Wed, 17 Mar 2010 13:20:00 GMT</pubDate>
    </item>
    <item>
      <title>Mannatech Vigorously Defends Ambrotose&amp;reg; Product Patents With Latest Legal Action Against Multiple Companies</title>
      <description>Mannatech, Incorporated, a global pioneer in the development of high-quality health, weight and fitness and skin care solutions based on nutritional science, announced it has filed a complaint against seven independent companies for infringement on Mannatech's patents (U.S. Patents 6,929,807; 7,157,431; 7,199,104; and 7,202,220). </description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Mannatech-Vigorously-Defends-Ambrotose-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Wed, 17 Mar 2010 13:15:00 GMT</pubDate>
    </item>
    <item>
      <title>Human Genome Sciences Announces Results Of Randomized Phase 2 Trial Of Mapatumumab In Nonsmall Cell Lung Cancer </title>
      <description>Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). </description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Human-Genome-Sciences-Announces-Results-Of-Ra-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Wed, 17 Mar 2010 13:11:00 GMT</pubDate>
    </item>
    <item>
      <title>Actavis Receives Approval of Alprazolam ODT in the U.S.</title>
      <description>Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food &amp; Drug Administration to market Alprazolam orally disintegrating tablets. Distribution of the product will commence immediately.  </description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Actavis-Receives-Approval-of-Alprazolam-ODT-i-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Wed, 17 Mar 2010 12:39:00 GMT</pubDate>
    </item>
    <item>
      <title>Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery For U.S. And States</title>
      <description>Alpharma Inc. has agreed to pay $42.5 million to the federal government and certain states to settle a whistleblower lawsuit that exposed an alleged kickback scheme by the pharmaceutical company to boost its sales of Kadian, a prescription painkiller.</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Whistleblower-Kickback-Case-Against-Alpharma-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Wed, 17 Mar 2010 12:27:00 GMT</pubDate>
    </item>
    <item>
      <title>Agendia To Play Pivotal Role In ISPY-2 Trial For Breast Cancer</title>
      <description>Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites. </description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Agendia-To-Play-Pivotal-Role-In-ISPY-2-Trial-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Wed, 17 Mar 2010 09:36:00 GMT</pubDate>
    </item>
    <item>
      <title>Biomanufacturing Courses Receive International Association For Continuing Education And Training (IACET) Certification</title>
      <description>Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, announced that its Access Knowledge Institute Courses for Biomanufacturing have been certified by the International Association for Continuing Education and Training (IACET) and authorized to grant continuing education credits.</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Biomanufacturing-Courses-Receive-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Wed, 17 Mar 2010 07:31:00 GMT</pubDate>
    </item>
    <item>
      <title>Comprehensive Microplate Catalogue</title>
      <description>The Porvair Sciences Product Catalogue for 2010 is packed with vital information on the company's wide range of microplates, plate sealers and microplate evaporators to help you get the best from your separations, assays and storage applications.</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Comprehensive-Microplate-Catalogue-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Wed, 17 Mar 2010 07:24:00 GMT</pubDate>
    </item>
    <item>
      <title>Accelerating Cell-Based ELISA Procedures</title>
      <description>Agilent Automation Solutions has announced a configuration of its BioCel System that allows laboratories to fully automate cell-based ELISA procedures thereby reducing the risk of human error, contamination and time spent on tedious manual procedures.</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Accelerating-Cell-Based-ELISA-Procedures-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Wed, 17 Mar 2010 07:20:00 GMT</pubDate>
    </item>
    <item>
      <title>BioTek's Synergy&amp;trade; H4 Hybrid Reader Is Transcreener&amp;reg; Approved</title>
      <description>BioTek's new Synergy H4 Hybrid Microplate Reader has received Transcreener approval from BellBrook Labs (Madison, WI). The approval extends to the Transcreener Fluorescence Polarization, Far Red, Red Fluorescence (FI) and Red TR-FRET assays, and means that the Synergy H4 meets strict standards in instrument setup and assay performance.</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/BioTeks-Synergy-H4-Hybrid-Reader-Is-0002?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Wed, 17 Mar 2010 06:34:00 GMT</pubDate>
    </item>
    <item>
      <title>K-Tron Process Group Introduces A New Material Flow Aid For Its Pharmaceutical Loss-In-Weight Feeders</title>
      <description>The K-Tron Process Group is proud to introduce ActiFlow&amp;trade; Smart Bulk Solids Activator, an innovative method to reliably prevent bridging and rat-holing of cohesive bulk materials in stainless steel hoppers without internal hopper agitation.</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/K-Tron-Process-Group-Introduces-A-New-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Wed, 17 Mar 2010 04:56:00 GMT</pubDate>
    </item>
    <item>
      <title>WHO Extends Prequalification Of Merck's ROTATEQ For Global Use</title>
      <description>ROTATEQ (Rotavirus Vaccine, Live, Oral, Pentavalent), the vaccine from Merck that helps prevent rotavirus gastroenteritis in infants and children, has received an extension of its prequalification status by the World Health Organization (WHO), to include its use in Asia and Africa.</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/WHO-Extends-Prequalification-Of-Mercks-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Tue, 16 Mar 2010 09:31:00 GMT</pubDate>
    </item>
    <item>
      <title>Anti-Obesity Drugs Unlikely To Provide Lasting Benefit According To Scientists</title>
      <description>Scientists at the University of Liverpool argue that anti-obesity drugs fail to provide lasting benefits for health and wellbeing because they tackle the biological consequences of obesity, and not the important psychological causes of overconsumption and weight gain.</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Anti-Obesity-Drugs-Unlikely-To-Provide-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Tue, 16 Mar 2010 09:14:00 GMT</pubDate>
    </item>
    <item>
      <title>Amylin, Lilly And Alkermes Receive Complete Response Letter From FDA For Exenatide Once Weekly Submission</title>
      <description>Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON(TM) (exenatide for extended-release injectable suspension).</description>
      <link>http://www.pharmaceuticalonline.com/article.mvc/Amylin-Lilly-And-Alkermes-Receive-Complete-R-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Mon, 15 Mar 2010 20:40:00 GMT</pubDate>
    </item>
    <item>
      <title>FDA Update: March 15, 2010</title>
      <description />
      <link>http://www.pharmaceuticalonline.com/article.mvc/FDA-Update-March-15-2010-0001?atc~c=771+s=773+r=001+l=a</link>
      <pubDate>Mon, 15 Mar 2010 18:27:00 GMT</pubDate>
    </item>
  </channel>
</rss>